Al-kuraishy HM, Jabir MS, Al-Gareeb AI, Albuhadily AK (2023) The conceivable role of prolactin hormone in Parkinson disease: the same goal but with different ways. Ageing Res Rev. https://doi.org/10.1016/j.arr.2023.102075

Article  PubMed  Google Scholar 

Alnaaim SA, Al-Kuraishy HM, Alexiou A, Papadakis M, Saad HM, Batiha GES (2024) Role of brain liver X receptor in Parkinson’s disease: hidden treasure and emerging opportunities. Mol Neurobiol 61:341–357. https://doi.org/10.1007/s12035-023-03561-y

Article  PubMed  CAS  Google Scholar 

Al-kuraishy HM, Al-Gareeb AI, Elewa YHA, Zahran MH, Alexiou A, Papadakis M, Batiha GES (2023) Parkinson’s disease risk and hyperhomocysteinemia: the possible link. Cell Mol Neurobiol 43:2743–2759. https://doi.org/10.1007/s10571-023-01350-8

Article  PubMed  PubMed Central  CAS  Google Scholar 

Al-kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Ahmed EA, Batiha GES (2023) SARS-COV-2 infection and Parkinson’s disease: possible links and perspectives. J Neurosci Res 101:952–975. https://doi.org/10.1002/jnr.25171

Article  PubMed  CAS  Google Scholar 

Ali NH, Al-kuraishy HM, Al-Gareeb AI, Alnaaim SA, Saad HM, Batiha GES (2024) The molecular pathway of p75 neurotrophin receptor (p75NTR) in Parkinson’s disease: the way of new inroads. Mol Neurobiol 61:2469–2480. https://doi.org/10.1007/s12035-023-03727-8

Article  PubMed  CAS  Google Scholar 

Alrouji M, Al-Kuraishy HM, Al-Mahammadawy AK, Al-Gareeb AI, Saad HM, Batiha GE (2023) The potential role of cholesterol in Parkinson’s disease neuropathology: perpetrator or victim. Neurol Sci 44:3781–3794. https://doi.org/10.1007/s10072-023-06926-2

Article  PubMed  Google Scholar 

Al-kuraishy HM, Al-Gareeb AI, Selim HM, Alexiou A, Papadakis M, Negm WA, Batiha GES (2024) Does vitamin D protect or treat Parkinson’s disease? A narrative review. Naunyn Schmiedebergs Arch Pharmacol 397:33–40. https://doi.org/10.1007/s00210-023-02656-6

Article  PubMed  CAS  Google Scholar 

Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Zaafar D, Batiha GES (2023) Orexin pathway in Parkinson’s disease: a review. Mol Biol Rep 50:6107–6120. https://doi.org/10.1007/s11033-023-08459-5

Article  PubMed  CAS  Google Scholar 

Al-Kuraishy HM, Al-Maiahy TJ, Al-Gareeb AI, Alexiou A, Papadakis M, Elhussieny O, Saad HM, Batiha GES (2023) New insights on the potential effect of progesterone in COVID-19: anti-inflammatory and immunosuppressive effects. Immun Inflamm Dis 11:0–1. https://doi.org/10.1002/iid3.1100

Article  CAS  Google Scholar 

Alrouji M, Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Jabir MS, Saad HM, Batiha GES (2023) NF-κB/NLRP3 inflammasome axis and risk of Parkinson’s disease in type 2 diabetes mellitus: a narrative review and new perspective. J Cell Mol Med 27:1775–1789. https://doi.org/10.1111/jcmm.17784

Article  PubMed  PubMed Central  CAS  Google Scholar 

Batiha GES, Al-kuraishy HM, Al-Gareeb AI, Elekhnawy E (2023) SIRT1 pathway in Parkinson’s disease: a faraway snapshot but so close. Inflammopharmacology 31:37–56. https://doi.org/10.1007/s10787-022-01125-5

Article  PubMed  CAS  Google Scholar 

Al-kuraishy HM, Al-Gareeb AI, Zaidalkiani AT, Alexiou A, Papadakis M, Bahaa MM, AL-Faraga A, Batiha GES (2024) Calprotectin in Parkinsonian disease: anticipation and dedication. Ageing Res Rev. https://doi.org/10.1016/j.arr.2023.102143

Article  PubMed  Google Scholar 

Alrouji M, Al-kuraishy HM, Al-buhadily AK, Al-Gareeb AI, Elekhnawy E, Batiha GES (2023) DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson’s disease: a mutual relationship. Pharmacol Rep 75:923–936. https://doi.org/10.1007/s43440-023-00500-5

Article  PubMed  CAS  Google Scholar 

Alrouji M, Al-kuraishy HM, Al-Gareeb AI, Ashour NA, Jabir MS, Negm WA, Batiha GES (2024) Metformin role in Parkinson’s disease: a double-sword effect. Mol Cell Biochem 479:975–991. https://doi.org/10.1007/s11010-023-04771-7

Article  PubMed  CAS  Google Scholar 

Al-Kuraishy H, Abdulhadi M, Hussien N, Al-Niemi M, Rasheed H, Al-Gareeb A (2020) Involvement of orexinergic system in psychiatric and neurodegenerative disorders: a scoping review. Brain Circ 6:70. https://doi.org/10.4103/bc.bc_42_19

Article  PubMed  PubMed Central  Google Scholar 

Ali NH, Alhamdan NA, Al-kuraishy HM, Al-Gareeb AI, Elekhnawy E, Batiha GES (2024) Irisin/PGC-1α/FNDC5 pathway in Parkinson’s disease: truth under the throes. Naunyn-Schmiedebergs Arch Pharmacol 397:1985–1995. https://doi.org/10.1007/s00210-023-02726-9

Article  PubMed  CAS  Google Scholar 

Borghammer P, Van Den Berge N (2019) Brain-First versus Gut-First Parkinson’s disease: a hypothesis. J Parkinsons Dis 9:S281–S295. https://doi.org/10.3233/JPD-191721

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cardinale A, Calabrese V, de Iure A, Picconi B (2021) Alpha-synuclein as a prominent actor in the inflammatory synaptopathy of parkinson’s disease. Int J Mol Sci 22:6517. https://doi.org/10.3390/ijms22126517

Article  PubMed  PubMed Central  CAS  Google Scholar 

Haque ME, Akther M, Azam S, Kim IS, Lin Y, Lee YH, Choi DK (2022) Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson’s disease. Br J Pharmacol 179:23–45. https://doi.org/10.1111/bph.15684

Article  PubMed  CAS  Google Scholar 

Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Krüger R, Müller T, Reichmann H, Rieß O, Storch A, Strobel S, van Eimeren T, Völker HU, Winkler J, Winklhofer KF, Wüllner U, Zunke F, Monoranu CM (2019) α-Synuclein in Parkinson’s disease: causal or bystander? J Neural Transm 126:815–840. https://doi.org/10.1007/s00702-019-02025-9

Article  PubMed  Google Scholar 

Kline EM, Houser MC, Herrick MK, Seibler P, Klein C, West A, Tansey MG (2021) Genetic and environmental factors in Parkinson’s disease converge on immune function and inflammation. Mov Disord 36:25–36. https://doi.org/10.1002/mds.28411

Article  PubMed  Google Scholar 

Feng ST, Wang ZZ, Yuan YH, Sun HM, Chen NH, Zhang Y (2021) Update on the association between alpha-synuclein and tau with mitochondrial dysfunction: implications for Parkinson’s disease. Eur J Neurosci 53:2946–2959. https://doi.org/10.1111/ejn.14699

Article  PubMed  Google Scholar 

Kasen A, Houck C, Burmeister AR, Sha Q, Brundin L, Brundin P (2022) Upregulation of α-synuclein following immune activation: possible trigger of Parkinson’s disease. Neurobiol Dis 166:105654. https://doi.org/10.1016/j.nbd.2022.105654

Article  PubMed  CAS  Google Scholar 

Chen L, Huang Y, Yu X, Lu J, Jia W, Song J, Liu L, Wang Y, Huang Y, Xie J, Li M (2021) Corynoxine protects dopaminergic neurons through inducing autophagy and diminishing neuroinflammation in rotenone-induced animal models of Parkinson’s disease. Front Pharmacol 12:642900. https://doi.org/10.3389/fphar.2021.642900

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lin CH, Chen PL, Tai CH, Lin HI, Chen CS, Chen ML, Wu RM (2019) A clinical and genetic study of early-onset and familial parkinsonism in taiwan: an integrated approach combining gene dosage analysis and next-generation sequencing. Mov Disord 34:506–515. https://doi.org/10.1002/mds.27633

Article  PubMed  PubMed Central  CAS  Google Scholar 

Trinh J, Guella I, Farrer MJ (2014) Disease penetrance of late-onset parkinsonism: a meta-analysis. JAMA Neurol 71:1535–1539. https://doi.org/10.1001/JAMANEUROL.2014.1909

Article  PubMed  Google Scholar 

Larsen SB, Hanss Z, Krüger R (2018) The genetic architecture of mitochondrial dysfunction in Parkinson’s disease. Cell Tissue Res 373:21–37. https://doi.org/10.1007/S00441-017-2768-8/FIGURES/3

Article  PubMed  PubMed Central  CAS